A5086583298- Bladder and Urothelial Cancer Treatments
- Urological Disorders and Treatments
- Urinary and Genital Oncology Studies
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
- Urinary Bladder and Prostate Research
- Cancer Immunotherapy and Biomarkers
- Tissue Engineering and Regenerative Medicine
- Ureteral procedures and complications
- Urologic and reproductive health conditions
- Pelvic floor disorders treatments
- Renal and related cancers
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
- Pediatric Urology and Nephrology Studies
- Immunotherapy and Immune Responses
- Radiopharmaceutical Chemistry and Applications
- Epigenetics and DNA Methylation
- Kidney Stones and Urolithiasis Treatments
- Urinary Tract Infections Management
- Cancer Cells and Metastasis
- Bone health and treatments
- Genital Health and Disease
- Cancer Diagnosis and Treatment
University of Tübingen
2016-2025
University Children's Hospital Tübingen
2016-2025
University of Montenegro
2024
European Association of Urology
2024
Universitätsklinikum Tübingen
2014-2023
Klinik und Poliklinik für Urologie
2006-2023
German Cancer Research Center
2014-2023
TH Bingen University of Applied Sciences
2022-2023
Oregon Health & Science University
2023
STZ eyetrial
2022
Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy safety of enzalutamide hormone-sensitive cancer (mHSPC).ARCHES (ClinicalTrials.gov identifier: NCT02677896) is multinational, double-blind, phase III trial, wherein 1,150 men with mHSPC were randomly assigned 1:1 to (160 mg/day) or placebo, plus androgen deprivation therapy (ADT), stratified by disease volume...
Purpose This phase III trial evaluated the efficacy and safety of pazopanib versus placebo in patients with locally advanced renal cell carcinoma (RCC) at high risk for relapse after nephrectomy. Patients Methods A total 1,538 resected pT2 (high grade) or ≥ pT3, including N1, clear RCC were randomly assigned to 1 year; 403 received a starting dose 800 mg placebo. To address toxicity attrition, 800-mg was lowered 600 mg, primary end point analysis changed disease-free survival (DFS) (n =...
No AccessJournal of UrologyAdult Urology1 Nov 2010Hexaminolevulinate Guided Fluorescence Cystoscopy Reduces Recurrence in Patients With Nonmuscle Invasive Bladder Cancer Arnulf Stenzl, Maximilian Burger, Yves Fradet, Lance A. Mynderse, Mark S. Soloway, J. Alfred Witjes, Martin Kriegmair, Alexander Karl, Yu Shen, and H. Barton Grossman StenzlArnulf Stenzl Department Urology, University Hospital, Tübingen, Germany Equal study contribution. More articles by this author , BurgerMaximilian Burger...
<h3>Background</h3> CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA (RNActive®) encoding the antigens PSA, PSCA, PSMA, and STEAP1. This phase I/IIa study evaluated safety immunogenicity of in patients with advanced castration-resistant prostate-cancer. <h3>Methods</h3> 44 Patients received up to 5 intra-dermal vaccinations. Three dose levels total were tested Phase I cohorts 3–6 determine recommended dose. In II, 32 additional treated at The primary endpoint was...